New antibiotic cocktail takes first step in human safety trial
NCT ID NCT06079775
First seen Nov 03, 2025 · Last updated Jun 22, 2026 · Updated 31 times
Summary
This early-stage trial tested the safety and drug interactions of an experimental oral antibiotic combination (QPX7831 plus ceftibuten) in 53 healthy adults. The goal was to see how the body processes the drugs and whether they cause side effects. Results will help decide safe doses for future studies in patients with bacterial infections.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BACTERIAL INFECTIONS are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
CMAX
Adelaide, South Australia, 5000, Australia
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
xeruborbactam oral prodrug (QPX7831) and ceftibuten
What this could lead to
If successful, this could lead to a new oral combination treatment for bacterial infections that are resistant to current antibiotics.
What could go wrong
This is an early Phase 1 study in only 53 healthy people, so it cannot yet show if the drug works against infections. Side effects may emerge in later trials.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.